{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:25:38Z","timestamp":1790637938895,"version":"4.1.0"},"reference-count":129,"publisher":"Springer Science and Business Media LLC","issue":"5-6","license":[{"start":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T00:00:00Z","timestamp":1713312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T00:00:00Z","timestamp":1713312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s00508-024-02358-w","type":"journal-article","created":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T13:02:36Z","timestamp":1714050156000},"page":"134-147","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Perspectives in treatment-resistant depression: esketamine and electroconvulsive therapy"],"prefix":"10.1007","volume":"137","author":[{"given":"Pia","family":"Baldinger-Melich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Spies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina","family":"Bozic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siegfried","family":"Kasper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Rujescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Frey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,17]]},"reference":[{"issue":"9","key":"2358_CR1","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1017\/S0033291717003336","volume":"48","author":"S Evans-Lacko","year":"2018","unstructured":"Evans-Lacko\u00a0S, Aguilar-Gaxiola\u00a0S, Al-Hamzawi\u00a0A, Alonso\u00a0J, Benjet\u00a0C, Bruffaerts\u00a0R, et\u00a0al. Socio-economic variations in the mental health treatment gap for people with anxiety, mood, and substance use disorders: results from the WHO World Mental Health (WMH) surveys. Psychol Med. 2018;48(9):1560\u201371.","journal-title":"Psychol Med"},{"issue":"3","key":"2358_CR2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/wps.21120","volume":"22","author":"RS McIntyre","year":"2023","unstructured":"McIntyre\u00a0RS, Alsuwaidan\u00a0M, Baune\u00a0BT, Berk\u00a0M, Demyttenaere\u00a0K, Goldberg\u00a0JF, et\u00a0al. Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions. World Psychiatry. 2023;22(3):394\u2013412.","journal-title":"World Psychiatry"},{"issue":"6","key":"2358_CR3","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1080\/15622975.2019.1635270","volume":"20","author":"L Bartova","year":"2019","unstructured":"Bartova\u00a0L, Dold\u00a0M, Kautzky\u00a0A, Fabbri\u00a0C, Spies\u00a0M, Serretti\u00a0A, et\u00a0al. Results of the European Group for the Study of Resistant Depression. (GSRD)\u2014basis for further research and clinical practice. World J Biol Psychiatry. 2019;20(6):427\u201348.","journal-title":"World J Biol Psychiatry"},{"issue":"6","key":"2358_CR4","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1080\/15622975.2020.1836399","volume":"22","author":"S Kasper","year":"2021","unstructured":"Kasper\u00a0S, Cuba\u0142a\u00a0WJ, Fagiolini\u00a0A, Ramos-Quiroga\u00a0JA, Souery\u00a0D, Young\u00a0AH. Practical recommendations for the management of treatment-resistant depression with esketamine nasal spray therapy: Basic science, evidence-based knowledge and expert guidance. World J Biol Psychiatry. 2021;22(6):468\u201382.","journal-title":"World J Biol Psychiatry"},{"issue":"1","key":"2358_CR5","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/acps.12959","volume":"139","author":"A Kautzky","year":"2019","unstructured":"Kautzky\u00a0A, Dold\u00a0M, Bartova\u00a0L, Spies\u00a0M, Kranz\u00a0GS, Souery\u00a0D, et\u00a0al. Clinical factors predicting treatment resistant depression: affirmative results from the European multicenter study. Acta Psychiatr Scand. 2019;139(1):78\u201388.","journal-title":"Acta Psychiatr Scand"},{"issue":"3","key":"2358_CR6","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/s41593-018-0326-7","volume":"22","author":"DM Howard","year":"2019","unstructured":"Howard\u00a0DM, Adams\u00a0MJ, Clarke\u00a0TK, Hafferty\u00a0JD, Gibson\u00a0J, Shirali\u00a0M, et\u00a0al. Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions. Nat Neurosci. 2019;22(3):343\u201352.","journal-title":"Nat Neurosci"},{"issue":"1","key":"2358_CR7","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41398-020-0738-5","volume":"10","author":"C Fabbri","year":"2020","unstructured":"Fabbri\u00a0C, Kasper\u00a0S, Kautzky\u00a0A, Zohar\u00a0J, Souery\u00a0D, Montgomery\u00a0S, et\u00a0al. A\u00a0polygenic predictor of treatment-resistant depression using whole exome sequencing and genome-wide genotyping. Transl Psychiatry. 2020;10(1):50.","journal-title":"Transl Psychiatry"},{"issue":"3","key":"2358_CR8","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/acps.12994","volume":"139","author":"A Bahji","year":"2019","unstructured":"Bahji\u00a0A, Hawken\u00a0ER, Sepehry\u00a0AA, Cabrera\u00a0CA, Vazquez\u00a0G. ECT beyond unipolar major depression: systematic review and meta-analysis of electroconvulsive therapy in bipolar depression. Acta Psychiatr Scand. 2019;139(3):214\u201326.","journal-title":"Acta Psychiatr Scand"},{"issue":"1","key":"2358_CR9","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1080\/13651501.2016.1254802","volume":"21","author":"C Kraus","year":"2017","unstructured":"Kraus\u00a0C, Rabl\u00a0U, Vanicek\u00a0T, Carlberg\u00a0L, Popovic\u00a0A, Spies\u00a0M, et\u00a0al. Administration of ketamine for unipolar and bipolar depression. Int J Psychiatry Clin Pract. 2017;21(1):2\u201312.","journal-title":"Int J Psychiatry Clin Pract"},{"key":"2358_CR10","unstructured":"Kasper S, Erfurth A, Sachs G, Aichhorn W, Bartova L, Bengesser S, et\u00a0al. Therapieresistente Depression: Diagnose und Behandlung, Konsensus-Statement. Sonderheft JATROS Neurologie. Psychiatrie. 2021;2021(03)."},{"issue":"1","key":"2358_CR11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/00124509-200403000-00004","volume":"20","author":"D Pagnin","year":"2004","unstructured":"Pagnin\u00a0D, de Queiroz\u00a0V, Pini\u00a0S, Cassano\u00a0GB. Efficacy of ECT in depression: a\u00a0meta-analytic review. J\u00a0Ect. 2004;20(1):13\u201320.","journal-title":"J Ect"},{"issue":"9360","key":"2358_CR12","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S0140-6736(03)12705-5","volume":"361","author":"UK ECT Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders","year":"2003","unstructured":"UK ECT Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders. a\u00a0systematic review and meta-analysis. Lancet. 2003;361(9360):799\u2013808.","journal-title":"Lancet"},{"issue":"1","key":"2358_CR13","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41398-019-0460-3","volume":"9","author":"C Kraus","year":"2019","unstructured":"Kraus\u00a0C, Kadriu\u00a0B, Lanzenberger\u00a0R, Zarate\u00a0CA Jr., Kasper\u00a0S. Prognosis and improved outcomes in major depression: a\u00a0review. Transl Psychiatry. 2019;9(1):127.","journal-title":"Transl Psychiatry"},{"key":"2358_CR14","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.eurpsy.2016.03.003","volume":"36","author":"WH Lee","year":"2016","unstructured":"Lee\u00a0WH, Lisanby\u00a0SH, Laine\u00a0AF, Peterchev\u00a0AV. Comparison of electric field strength and spatial distribution of electroconvulsive therapy and magnetic seizure therapy in a\u00a0realistic human head model. Eur Psychiatry. 2016;36:55\u201364.","journal-title":"Eur Psychiatry"},{"key":"2358_CR15","doi-asserted-by":"crossref","unstructured":"Deng ZD, Robins PL, Regenold W, Rohde P, Dannhauer M, Lisanby SH. How electroconvulsive therapy works in the treatment of depression: is it the seizure, the electricity, or both? Neuropsychopharmacology. 2023;.","DOI":"10.1038\/s41386-023-01677-2"},{"key":"2358_CR16","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.bbr.2016.11.028","volume":"320","author":"JJ Chen","year":"2017","unstructured":"Chen\u00a0JJ, Zhao\u00a0LB, Liu\u00a0YY, Fan\u00a0SH, Xie\u00a0P. Comparative efficacy and acceptability of electroconvulsive therapy versus repetitive transcranial magnetic stimulation for major depression: A\u00a0systematic review and multiple-treatments meta-analysis. Behav Brain Res. 2017;320:30\u20136.","journal-title":"Behav Brain Res"},{"key":"2358_CR17","unstructured":"Conca A, Hinterhuber H, Prapotnik M, Geretsegger C, Frey R, Hausmann A, et\u00a0al. Die Elektrokrampftherapie: Theorie und Praxis. Neuropsychiatrie. 2004;."},{"issue":"March","key":"2358_CR18","first-page":"141","volume":"3","author":"H Folkerts","year":"2003","unstructured":"Folkerts\u00a0H, Remschmidt\u00a0H, Sa\u00df\u00a0H, Sauer\u00a0H, Sch\u00e4fer\u00a0M, Sewing\u00a0K\u2011F. Bekanntmachung des Bundes\u00e4rztekammer: Stellungnahme zur Elektrokrampftherapie (EKT) als psychiatrische Behandlungsma\u00dfnahme. Dtsch \u00c4rztebl. 2003;3(March):141.","journal-title":"Dtsch \u00c4rztebl"},{"issue":"1","key":"2358_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00737-013-0389-0","volume":"18","author":"KA Leiknes","year":"2015","unstructured":"Leiknes\u00a0KA, Cooke\u00a0MJ, Jarosch-von Schweder\u00a0L, Harboe\u00a0I, H\u00f8ie\u00a0B. Electroconvulsive therapy during pregnancy: a\u00a0systematic review of case studies. Arch Womens Ment Health. 2015;18(1):1\u201339.","journal-title":"Arch Womens Ment Health"},{"issue":"6","key":"2358_CR20","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.biopsych.2010.06.009","volume":"68","author":"M Semkovska","year":"2010","unstructured":"Semkovska\u00a0M, McLoughlin\u00a0DM. Objective cognitive performance associated with electroconvulsive therapy for depression: a\u00a0systematic review and meta-analysis. Biol Psychiatry. 2010;68(6):568\u201377.","journal-title":"Biol Psychiatry"},{"issue":"3","key":"2358_CR21","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/acps.12942","volume":"138","author":"J Obbels","year":"2018","unstructured":"Obbels\u00a0J, Verwijk\u00a0E, Vansteelandt\u00a0K, Dols\u00a0A, Bouckaert\u00a0F, Schouws\u00a0S, et\u00a0al. Long-term neurocognitive functioning after electroconvulsive therapy in patients with late-life depression. Acta Psychiatr Scand. 2018;138(3):223\u201331.","journal-title":"Acta Psychiatr Scand"},{"key":"2358_CR22","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.4088\/JCP.14r09528","volume":"76(10","author":"AU Haq","year":"2015","unstructured":"Haq\u00a0AU, Sitzmann\u00a0AF, Goldman\u00a0ML, Maixner\u00a0DF, Mickey\u00a0BJ. Response of depression to electroconvulsive therapy: a\u00a0meta-analysis of clinical predictors. J\u00a0Clin Psychiatry. 2015;76(10:1374\u201384.","journal-title":"J Clin Psychiatry"},{"issue":"8","key":"2358_CR23","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1176\/ajp.153.8.985","volume":"153","author":"J Prudic","year":"1996","unstructured":"Prudic\u00a0J, Haskett\u00a0RF, Mulsant\u00a0B, Malone\u00a0KM, Pettinati\u00a0HM, Stephens\u00a0S, et\u00a0al. Resistance to antidepressant medications and short-term clinical response to ECT. Am J Psychiatry. 1996;153(8):985\u201392.","journal-title":"Am J Psychiatry"},{"key":"2358_CR24","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.neulet.2016.10.047","volume":"669","author":"M Pinna","year":"2018","unstructured":"Pinna\u00a0M, Manchia\u00a0M, Oppo\u00a0R, Scano\u00a0F, Pillai\u00a0G, Loche\u00a0AP, et\u00a0al. Clinical and biological predictors of response to electroconvulsive therapy (ECT): a\u00a0review. Neurosci Lett. 2018;669:32\u201342.","journal-title":"Neurosci Lett"},{"key":"2358_CR25","doi-asserted-by":"crossref","unstructured":"van Diermen L, van den Ameele S, Kamperman AM, Sabbe BCG, Vermeulen T, Schrijvers D, Birkenh\u00e4ger TK. Prediction of electroconvulsive therapy response and remission in major depression: meta-analysis. The British journal of psychiatry : the journal of mental science. 2018;212(2):71\u201380.","DOI":"10.1192\/bjp.2017.28"},{"issue":"11","key":"2358_CR26","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1176\/appi.ajp.2016.15081101","volume":"173","author":"CH Kellner","year":"2016","unstructured":"Kellner\u00a0CH, Husain\u00a0MM, Knapp\u00a0RG, McCall\u00a0WV, Petrides\u00a0G, Rudorfer\u00a0MV, et\u00a0al. Right Unilateral Ultrabrief Pulse ECT in Geriatric Depression: Phase\u00a01 of the PRIDE Study. Am J Psychiatry. 2016;173(11):1101\u20139.","journal-title":"Am J Psychiatry"},{"key":"2358_CR27","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jad.2004.05.006","volume":"83(2\u20133","author":"SS Husain","year":"2004","unstructured":"Husain\u00a0SS, Kevan\u00a0IM, Linnell\u00a0R, Scott\u00a0AI. Electroconvulsive therapy in depressive illness that has not responded to drug treatment. J\u00a0Affect Disord. 2004;83(2\u20133:121\u20136.","journal-title":"J Affect Disord"},{"key":"2358_CR28","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1001\/archpsyc.57.5.438","volume":"57(5","author":"WV McCall","year":"2000","unstructured":"McCall\u00a0WV, Reboussin\u00a0DM, Weiner\u00a0RD, Sackeim\u00a0HA. Titrated moderately suprathreshold vs fixed high-dose right unilateral electroconvulsive therapy: acute antidepressant and cognitive effects. Arch Gen Psychiatry. 2000;57(5:438\u201344.","journal-title":"Arch Gen Psychiatry"},{"issue":"8","key":"2358_CR29","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s00406-018-0910-6","volume":"268","author":"L Kranaster","year":"2018","unstructured":"Kranaster\u00a0L, Aksay\u00a0SS, Bumb\u00a0JM, Hoyer\u00a0C, Jennen-Steinmetz\u00a0C, Sartorius\u00a0A. A\u00a0novel Seizure Quality Index based on ictal parameters for optimizing clinical decision making in electroconvulsive therapy. Part 1: development. Eur Arch Psychiatry Clin Neurosci. 2018;268(8):819\u201330.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"5","key":"2358_CR30","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1001\/archpsyc.57.5.425","volume":"57","author":"HA Sackeim","year":"2000","unstructured":"Sackeim\u00a0HA, Prudic\u00a0J, Devanand\u00a0DP, Nobler\u00a0MS, Lisanby\u00a0SH, Peyser\u00a0S, et\u00a0al. A\u00a0prospective, randomized, double-blind comparison of bilateral and right unilateral electroconvulsive therapy at different stimulus intensities. Arch Gen Psychiatry. 2000;57(5):425\u201334.","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"2358_CR31","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1097\/00124509-200106000-00004","volume":"17","author":"R Frey","year":"2001","unstructured":"Frey\u00a0R, Heiden\u00a0A, Scharfetter\u00a0J, Schreinzer\u00a0D, Blasbichler\u00a0T, Tauscher\u00a0J, et\u00a0al. Inverse relation between stimulus intensity and seizure duration: implications for ECT procedure. J\u00a0Ect. 2001;17(2):102\u20138.","journal-title":"J Ect"},{"key":"2358_CR32","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/YCT.0000000000000085","volume":"30(3","author":"ED Brown","year":"2014","unstructured":"Brown\u00a0ED, Lee\u00a0H, Scott\u00a0D, Cummings\u00a0GG. Efficacy of continuation\/maintenance electroconvulsive therapy for the prevention of recurrence of a\u00a0major depressive episode in adults with unipolar depression: a\u00a0systematic review. J\u00a0Ect. 2014;30(3:195\u2013202.","journal-title":"J Ect"},{"issue":"11","key":"2358_CR33","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1176\/appi.ajp.2016.16010118","volume":"173","author":"CH Kellner","year":"2016","unstructured":"Kellner\u00a0CH, Husain\u00a0MM, Knapp\u00a0RG, McCall\u00a0WV, Petrides\u00a0G, Rudorfer\u00a0MV, et\u00a0al. A\u00a0Novel Strategy for Continuation ECT in Geriatric Depression: Phase\u00a02 of the PRIDE Study. Am J Psychiatry. 2016;173(11):1110\u20138.","journal-title":"Am J Psychiatry"},{"issue":"4","key":"2358_CR34","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.brs.2021.05.014","volume":"14","author":"G Gryglewski","year":"2021","unstructured":"Gryglewski\u00a0G, Lanzenberger\u00a0R, Silberbauer\u00a0LR, Pacher\u00a0D, Kasper\u00a0S, Rupprecht\u00a0R, et\u00a0al. Meta-analysis of brain structural changes after electroconvulsive therapy in depression. Brain Stimul. 2021;14(4):927\u201337.","journal-title":"Brain Stimul"},{"issue":"2","key":"2358_CR35","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1017\/S0033291719003660","volume":"50","author":"V Enneking","year":"2020","unstructured":"Enneking\u00a0V, Leehr\u00a0EJ, Dannlowski\u00a0U, Redlich\u00a0R. Brain structural effects of treatments for depression and biomarkers of response: a\u00a0systematic review of neuroimaging studies. Psychol Med. 2020;50(2):187\u2013209.","journal-title":"Psychol Med"},{"key":"2358_CR36","doi-asserted-by":"crossref","unstructured":"Gryglewski G, Baldinger-Melich P, Seiger R, Godbersen GM, Michenthaler P, Kl\u00f6bl M, et\u00a0al. Structural changes in amygdala nuclei, hippocampal subfields and cortical thickness following electroconvulsive therapy in treatment-resistant depression: longitudinal analysis. The British journal of psychiatry : the journal of mental science. 2019;214(3):159\u201367.","DOI":"10.1192\/bjp.2018.224"},{"key":"2358_CR37","doi-asserted-by":"publisher","first-page":"110178","DOI":"10.1016\/j.pnpbp.2020.110178","volume":"108","author":"D Porta-Caster\u00e0s","year":"2021","unstructured":"Porta-Caster\u00e0s\u00a0D, Cano\u00a0M, Camprodon\u00a0JA, Loo\u00a0C, Palao\u00a0D, Soriano-Mas\u00a0C, Cardoner\u00a0N. A\u00a0multimetric systematic review of fMRI findings in patients with MDD receiving ECT. Prog Neuropsychopharmacol Biol Psychiatry. 2021;108:110178.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"2358_CR38","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1097\/YCT.0000000000000138","volume":"30(2","author":"P Baldinger","year":"2014","unstructured":"Baldinger\u00a0P, Lotan\u00a0A, Frey\u00a0R, Kasper\u00a0S, Lerer\u00a0B, Lanzenberger\u00a0R. Neurotransmitters and electroconvulsive therapy. J\u00a0Ect. 2014;30(2:116\u201321.","journal-title":"J Ect"},{"issue":"3","key":"2358_CR39","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.brs.2018.12.976","volume":"12","author":"P Baldinger-Melich","year":"2019","unstructured":"Baldinger-Melich\u00a0P, Gryglewski\u00a0G, Philippe\u00a0C, James\u00a0GM, Vraka\u00a0C, Silberbauer\u00a0L, et\u00a0al. The effect of electroconvulsive therapy on cerebral monoamine oxidase A expression in treatment-resistant depression investigated using positron emission tomography. Brain Stimul. 2019;12(3):714\u201323.","journal-title":"Brain Stimul"},{"issue":"1","key":"2358_CR40","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/mp.2012.93","volume":"18","author":"R Lanzenberger","year":"2013","unstructured":"Lanzenberger\u00a0R, Baldinger\u00a0P, Hahn\u00a0A, Ungersboeck\u00a0J, Mitterhauser\u00a0M, Winkler\u00a0D, et\u00a0al. Global decrease of serotonin-1A receptor binding after electroconvulsive therapy in major depression measured by PET. Mol Psychiatry. 2013;18(1):93\u2013100.","journal-title":"Mol Psychiatry"},{"key":"2358_CR41","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jpsychires.2016.08.004","volume":"83","author":"RB Rocha","year":"2016","unstructured":"Rocha\u00a0RB, Dondossola\u00a0ER, Grande\u00a0AJ, Colonetti\u00a0T, Ceretta\u00a0LB, Passos\u00a0IC, et\u00a0al. Increased BDNF levels after electroconvulsive therapy in patients with major depressive disorder: A\u00a0meta-analysis study. J\u00a0Psychiatr Res. 2016;83:47\u201353.","journal-title":"J Psychiatr Res"},{"issue":"5","key":"2358_CR42","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3109\/15622975.2014.892633","volume":"15","author":"AR Brunoni","year":"2014","unstructured":"Brunoni\u00a0AR, Baeken\u00a0C, Machado-Vieira\u00a0R, Gattaz\u00a0WF, Vanderhasselt\u00a0MA. BDNF blood levels after electroconvulsive therapy in patients with mood disorders: a\u00a0systematic review and meta-analysis. World J Biol Psychiatry. 2014;15(5):411\u20138.","journal-title":"World J Biol Psychiatry"},{"issue":"5","key":"2358_CR43","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1111\/acps.13080","volume":"140","author":"T Vanicek","year":"2019","unstructured":"Vanicek\u00a0T, Kranz\u00a0GS, Vyssoki\u00a0B, Komorowski\u00a0A, Fugger\u00a0G, H\u00f6flich\u00a0A, et\u00a0al. Repetitive enhancement of serum BDNF subsequent to continuation ECT. Acta Psychiatr Scand. 2019;140(5):426\u201334.","journal-title":"Acta Psychiatr Scand"},{"key":"2358_CR44","doi-asserted-by":"publisher","first-page":"109171","DOI":"10.1016\/j.neuropharm.2022.109171","volume":"216","author":"K Hirota","year":"2022","unstructured":"Hirota\u00a0K, Lambert\u00a0DG. Ketamine; history and role in anesthetic pharmacology. Neuropharmacology. 2022;216:109171.","journal-title":"Neuropharmacology"},{"key":"2358_CR45","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jpsychires.2021.02.020","volume":"137","author":"B Sanders","year":"2021","unstructured":"Sanders\u00a0B, Brula\u00a0AQ. Intranasal esketamine: From origins to future implications in treatment-resistant depression. J\u00a0Psychiatr Res. 2021;137:29\u201335.","journal-title":"J Psychiatr Res"},{"key":"2358_CR46","doi-asserted-by":"crossref","unstructured":"Riccardi A, Guarino M, Serra S, Spampinato MD, Vanni S, Shiffer D, et\u00a0al. Narrative Review: Low-Dose Ketamine for Pain Management. J\u00a0Clin Med. 2023;12(9).","DOI":"10.3390\/jcm12093256"},{"issue":"1","key":"2358_CR47","first-page":"47","volume":"62","author":"S Loix","year":"2011","unstructured":"Loix\u00a0S, De Kock\u00a0M, Henin\u00a0P. The anti-inflammatory effects of ketamine: state of the art. Acta Anaesthesiol Belg. 2011;62(1):47\u201358.","journal-title":"Acta Anaesthesiol Belg"},{"issue":"8","key":"2358_CR48","first-page":"3116","volume":"27","author":"HK Ketamine","year":"2022","unstructured":"Ketamine\u00a0HK. anesthetic, psychotomimetic, antidepressant, or anthelmintic? Mol. Psychiatry. 2022;27(8):3116\u20138.","journal-title":"Psychiatry"},{"issue":"3","key":"2358_CR49","doi-asserted-by":"publisher","first-page":"283","DOI":"10.4103\/0259-1162.143110","volume":"8","author":"MS Kurdi","year":"2014","unstructured":"Kurdi\u00a0MS, Theerth\u00a0KA, Ketamine\u00a0DRS. Current applications in anesthesia, pain, and critical care. Anesth Essays Res. 2014;8(3):283\u201390.","journal-title":"Anesth Essays Res"},{"key":"2358_CR50","doi-asserted-by":"publisher","first-page":"109219","DOI":"10.1016\/j.neuropharm.2022.109219","volume":"218","author":"JC Zhang","year":"2022","unstructured":"Zhang\u00a0JC, Yao\u00a0W, Hashimoto\u00a0K. Arketamine, a\u00a0new rapid-acting antidepressant: A\u00a0historical review and future directions. Neuropharmacology. 2022;218:109219.","journal-title":"Neuropharmacology"},{"key":"2358_CR51","doi-asserted-by":"publisher","first-page":"109305","DOI":"10.1016\/j.neuropharm.2022.109305","volume":"222","author":"K Zhang","year":"2023","unstructured":"Zhang\u00a0K, Yao\u00a0Y, Hashimoto\u00a0K. Ketamine and its metabolites: Potential as novel treatments for depression. Neuropharmacology. 2023;222:109305.","journal-title":"Neuropharmacology"},{"issue":"7604","key":"2358_CR52","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature17998","volume":"533","author":"P Zanos","year":"2016","unstructured":"Zanos\u00a0P, Moaddel\u00a0R, Morris\u00a0PJ, Georgiou\u00a0P, Fischell\u00a0J, Elmer\u00a0GI, et\u00a0al. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature. 2016;533(7604):481\u20136.","journal-title":"Nature"},{"issue":"3","key":"2358_CR53","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.117.015198","volume":"70","author":"P Zanos","year":"2018","unstructured":"Zanos\u00a0P, Moaddel\u00a0R, Morris\u00a0PJ, Riggs\u00a0LM, Highland\u00a0JN, Georgiou\u00a0P, et\u00a0al. Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms. Pharmacol Rev. 2018;70(3):621\u201360.","journal-title":"Pharmacol Rev"},{"issue":"Suppl 2","key":"2358_CR54","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1055\/s-2007-979354","volume":"31","author":"WM Abi-Saab","year":"1998","unstructured":"Abi-Saab\u00a0WM, D\u2019Souza\u00a0DC, Moghaddam\u00a0B, Krystal\u00a0JH. The NMDA antagonist model for schizophrenia: promise and pitfalls. Pharmacopsychiatry. 1998;31(Suppl 2):104\u20139.","journal-title":"Pharmacopsychiatry"},{"issue":"4","key":"2358_CR55","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","volume":"47","author":"RM Berman","year":"2000","unstructured":"Berman\u00a0RM, Cappiello\u00a0A, Anand\u00a0A, Oren\u00a0DA, Heninger\u00a0GR, Charney\u00a0DS, Krystal\u00a0JH. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351\u20134.","journal-title":"Biol Psychiatry"},{"issue":"8","key":"2358_CR56","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","volume":"63","author":"CA Zarate Jr.","year":"2006","unstructured":"Zarate\u00a0CA Jr., Singh\u00a0JB, Carlson\u00a0PJ, Brutsche\u00a0NE, Ameli\u00a0R, Luckenbaugh\u00a0DA, et\u00a0al. A\u00a0randomized trial of an N\u2011methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856\u201364.","journal-title":"Arch Gen Psychiatry"},{"issue":"8","key":"2358_CR57","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1001\/archgenpsychiatry.2010.90","volume":"67","author":"N Diazgranados","year":"2010","unstructured":"Diazgranados\u00a0N, Ibrahim\u00a0L, Brutsche\u00a0NE, Newberg\u00a0A, Kronstein\u00a0P, Khalife\u00a0S, et\u00a0al. A\u00a0randomized add-on trial of an N\u2011methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry. 2010;67(8):793\u2013802.","journal-title":"Arch Gen Psychiatry"},{"issue":"5","key":"2358_CR58","doi-asserted-by":"publisher","first-page":"e619","DOI":"10.4088\/JCP.14r09767","volume":"77","author":"GI Papakostas","year":"2016","unstructured":"Papakostas\u00a0GI, Martinson\u00a0MA, Fava\u00a0M, Iovieno\u00a0N. Demographic variables, design characteristics, and effect sizes of randomized, placebo-controlled, monotherapy trials of major depressive disorder and bipolar depression. J\u00a0Clin Psychiatry. 2016;77(5):e619\u201324.","journal-title":"J Clin Psychiatry"},{"key":"2358_CR59","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1097\/01.pra.0000430506.37144.d1","volume":"19(3","author":"SH Preskorn","year":"2013","unstructured":"Preskorn\u00a0SH. Declining differences in response rates with antidepressants versus placebo: a\u00a0modest proposal for another contributing cause. J\u00a0Psychiatr Pract. 2013;19(3:227\u201333.","journal-title":"J Psychiatr Pract"},{"key":"2358_CR60","doi-asserted-by":"crossref","unstructured":"Murrough JW, Perez AM, Pillemer S, Stern J, Parides MK, aan het Rot M, et\u00a0al. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry. 2013;74(4):250\u20136.","DOI":"10.1016\/j.biopsych.2012.06.022"},{"issue":"5","key":"2358_CR61","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1176\/appi.ajp.2018.18070834","volume":"176","author":"JL Phillips","year":"2019","unstructured":"Phillips\u00a0JL, Norris\u00a0S, Talbot\u00a0J, Birmingham\u00a0M, Hatchard\u00a0T, Ortiz\u00a0A, et\u00a0al. Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A\u00a0Randomized Controlled Trial. Am J Psychiatry. 2019;176(5):401\u20139.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"2358_CR62","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41398-020-00897-0","volume":"10","author":"PR Shiroma","year":"2020","unstructured":"Shiroma\u00a0PR, Thuras\u00a0P, Wels\u00a0J, Albott\u00a0CS, Erbes\u00a0C, Tye\u00a0S, Lim\u00a0KO. A\u00a0randomized, double-blind, active placebo-controlled study of efficacy, safety, and durability of repeated vs single subanesthetic ketamine for treatment-resistant depression. Transl Psychiatry. 2020;10(1):206.","journal-title":"Transl Psychiatry"},{"key":"2358_CR63","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.jad.2020.06.050","volume":"276","author":"RS McIntyre","year":"2020","unstructured":"McIntyre\u00a0RS, Carvalho\u00a0IP, Lui\u00a0LMW, Majeed\u00a0A, Masand\u00a0PS, Gill\u00a0H, et\u00a0al. The effect of intravenous, intranasal, and oral ketamine in mood disorders: A\u00a0meta-analysis. J\u00a0Affect Disord. 2020;276:576\u201384.","journal-title":"J Affect Disord"},{"issue":"9","key":"2358_CR64","doi-asserted-by":"publisher","first-page":"e932","DOI":"10.4088\/JCP.14m09049","volume":"75","author":"DF Ionescu","year":"2014","unstructured":"Ionescu\u00a0DF, Luckenbaugh\u00a0DA, Niciu\u00a0MJ, Richards\u00a0EM, Slonena\u00a0EE, Vande Voort\u00a0JL, et\u00a0al. Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine. J\u00a0Clin Psychiatry. 2014;75(9):e932\u20138.","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"2358_CR65","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1176\/appi.ajp.2020.20050596","volume":"178","author":"A Feder","year":"2021","unstructured":"Feder\u00a0A, Costi\u00a0S, Rutter\u00a0SB, Collins\u00a0AB, Govindarajulu\u00a0U, Jha\u00a0MK, et\u00a0al. A\u00a0Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder. Am J Psychiatry. 2021;178(2):193\u2013202.","journal-title":"Am J Psychiatry"},{"key":"2358_CR66","doi-asserted-by":"publisher","first-page":"115133","DOI":"10.1016\/j.psychres.2023.115133","volume":"323","author":"K Danayan","year":"2023","unstructured":"Danayan\u00a0K, Chisamore\u00a0N, Rodrigues\u00a0NB, Vincenzo\u00a0JDD, Meshkat\u00a0S, Doyle\u00a0Z, et\u00a0al. Real world effectiveness of repeated ketamine infusions for treatment-resistant depression with comorbid borderline personality disorder. Psychiatry Res. 2023;323:115133.","journal-title":"Psychiatry Res"},{"issue":"8","key":"2358_CR67","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1089\/jpm.2012.0617","volume":"16","author":"SA Irwin","year":"2013","unstructured":"Irwin\u00a0SA, Iglewicz\u00a0A, Nelesen\u00a0RA, Lo\u00a0JY, Carr\u00a0CH, Romero\u00a0SD, Lloyd\u00a0LS. Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: a\u00a028-day open-label proof-of-concept trial. J\u00a0Palliat Med. 2013;16(8):958\u201365.","journal-title":"J Palliat Med"},{"issue":"12","key":"2358_CR68","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.biopsych.2014.03.026","volume":"76","author":"KA Lapidus","year":"2014","unstructured":"Lapidus\u00a0KA, Levitch\u00a0CF, Perez\u00a0AM, Brallier\u00a0JW, Parides\u00a0MK, Soleimani\u00a0L, et\u00a0al. A\u00a0randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry. 2014;76(12):970\u20136.","journal-title":"Biol Psychiatry"},{"key":"2358_CR69","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.jad.2018.02.056","volume":"235","author":"S Arabzadeh","year":"2018","unstructured":"Arabzadeh\u00a0S, Hakkikazazi\u00a0E, Shahmansouri\u00a0N, Tafakhori\u00a0A, Ghajar\u00a0A, Jafarinia\u00a0M, Akhondzadeh\u00a0S. Does oral administration of ketamine accelerate response to treatment in major depressive disorder? Results of a\u00a0double-blind controlled trial. J\u00a0Affect Disord. 2018;235:236\u201341.","journal-title":"J Affect Disord"},{"issue":"1","key":"2358_CR70","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/acps.12572","volume":"134","author":"CK Loo","year":"2016","unstructured":"Loo\u00a0CK, Galvez\u00a0V, O\u2019Keefe\u00a0E, Mitchell\u00a0PB, Hadzi-Pavlovic\u00a0D, Leyden\u00a0J, et\u00a0al. Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression. Acta Psychiatr Scand. 2016;134(1):48\u201356.","journal-title":"Acta Psychiatr Scand"},{"key":"2358_CR71","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.jad.2019.11.086","volume":"264","author":"FS Correia-Melo","year":"2020","unstructured":"Correia-Melo\u00a0FS, Leal\u00a0GC, Vieira\u00a0F, Jesus-Nunes\u00a0AP, Mello\u00a0RP, Magnavita\u00a0G, et\u00a0al. Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: A\u00a0randomized, double-blind, non-inferiority study. J\u00a0Affect Disord. 2020;264:527\u201334.","journal-title":"J Affect Disord"},{"issue":"3","key":"2358_CR72","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/papr.12961","volume":"21","author":"Y Bi","year":"2021","unstructured":"Bi\u00a0Y, Ye\u00a0Y, Zhu\u00a0Y, Ma\u00a0J, Zhang\u00a0X, Liu\u00a0B. The Effect of Ketamine on Acute and Chronic Wound Pain in Patients Undergoing Breast Surgery: A\u00a0Meta-Analysis and Systematic Review. Pain Pract. 2021;21(3):316\u201332.","journal-title":"Pain Pract"},{"key":"2358_CR73","first-page":"e922028","volume":"26","author":"J Wang","year":"2020","unstructured":"Wang\u00a0J, Wang\u00a0Y, Xu\u00a0X, Peng\u00a0S, Xu\u00a0F, Liu\u00a0P. Use of Various Doses of S\u2011Ketamine in Treatment of Depression and Pain in Cervical Carcinoma Patients with Mild\/Moderate Depression After Laparoscopic Total Hysterectomy. Med Sci Monit. 2020;26:e922028.","journal-title":"Med Sci Monit"},{"issue":"7","key":"2358_CR74","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1176\/appi.ajp.2018.17060720","volume":"175","author":"CM Canuso","year":"2018","unstructured":"Canuso\u00a0CM, Singh\u00a0JB, Fedgchin\u00a0M, Alphs\u00a0L, Lane\u00a0R, Lim\u00a0P, et\u00a0al. Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a\u00a0Double-Blind, Randomized, Placebo-Controlled Study. Am J Psychiatry. 2018;175(7):620\u201330.","journal-title":"Am J Psychiatry"},{"key":"2358_CR75","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1001\/jamapsychiatry.2017.3739","volume":"75(2","author":"EJ Daly","year":"2018","unstructured":"Daly\u00a0EJ, Singh\u00a0JB, Fedgchin\u00a0M, Cooper\u00a0K, Lim\u00a0P, Shelton\u00a0RC, et\u00a0al. Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A\u00a0Randomized Clinical Trial. Jama Psychiatry. 2018;75(2:139\u201348.","journal-title":"Jama Psychiatry"},{"issue":"10","key":"2358_CR76","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1093\/ijnp\/pyz039","volume":"22","author":"M Fedgchin","year":"2019","unstructured":"Fedgchin\u00a0M, Trivedi\u00a0M, Daly\u00a0EJ, Melkote\u00a0R, Lane\u00a0R, Lim\u00a0P, et\u00a0al. Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a\u00a0New Oral Antidepressant in Treatment-Resistant Depression: Results of a\u00a0Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1). Int J Neuropsychopharmacol. 2019;22(10):616\u201330.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"6","key":"2358_CR77","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1176\/appi.ajp.2019.19020172","volume":"176","author":"V Popova","year":"2019","unstructured":"Popova\u00a0V, Daly\u00a0EJ, Trivedi\u00a0M, Cooper\u00a0K, Lane\u00a0R, Lim\u00a0P, et\u00a0al. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a\u00a0Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A\u00a0Randomized Double-Blind Active-Controlled Study. Am J Psychiatry. 2019;176(6):428\u201338.","journal-title":"Am J Psychiatry"},{"key":"2358_CR78","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jagp.2019.10.008","volume":"28(2","author":"R Ochs-Ross","year":"2020","unstructured":"Ochs-Ross\u00a0R, Daly\u00a0EJ, Zhang\u00a0Y, Lane\u00a0R, Lim\u00a0P, Morrison\u00a0RL, et\u00a0al. Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression-TRANSFORM\u20113. Am J Geriatr Psychiatry. 2020;28(2):121\u201341.","journal-title":"Am J Geriatr Psychiatry"},{"key":"2358_CR79","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1001\/jamapsychiatry.2019.1189","volume":"76(9","author":"EJ Daly","year":"2019","unstructured":"Daly\u00a0EJ, Trivedi\u00a0MH, Janik\u00a0A, Li\u00a0H, Zhang\u00a0Y, Li\u00a0X, et\u00a0al. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A\u00a0Randomized Clinical Trial. Jama Psychiatry. 2019;76(9):893\u2013903.","journal-title":"Jama Psychiatry"},{"key":"2358_CR80","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4088\/JCP.19m12891","volume":"81","author":"E Wajs","year":"2020","unstructured":"Wajs\u00a0E, Aluisio\u00a0L, Holder\u00a0R, Daly\u00a0EJ, Lane\u00a0R, Lim\u00a0P, et\u00a0al. Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a\u00a0Phase\u00a03, Open-Label Study (SUSTAIN-2). J\u00a0Clin Psychiatry. 2020;81:3.","journal-title":"J Clin Psychiatry"},{"key":"2358_CR81","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4088\/JCP.19m13191","volume":"81","author":"DJ Fu","year":"2020","unstructured":"Fu\u00a0DJ, Ionescu\u00a0DF, Li\u00a0X, Lane\u00a0R, Lim\u00a0P, Sanacora\u00a0G, et\u00a0al. Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I). J\u00a0Clin Psychiatry. 2020;81:3.","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"2358_CR82","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1093\/ijnp\/pyaa068","volume":"24","author":"DF Ionescu","year":"2021","unstructured":"Ionescu\u00a0DF, Fu\u00a0DJ, Qiu\u00a0X, Lane\u00a0R, Lim\u00a0P, Kasper\u00a0S, et\u00a0al. Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a\u00a0Phase\u00a03, Double-Blind, Randomized Study (ASPIRE II). Int J Neuropsychopharmacol. 2021;24(1):22\u201331.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"14","key":"2358_CR83","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1056\/NEJMoa2304145","volume":"389","author":"A Reif","year":"2023","unstructured":"Reif\u00a0A, Bitter\u00a0I, Buyze\u00a0J, Cebulla\u00a0K, Frey\u00a0R, Fu\u00a0DJ, et\u00a0al. Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression. N\u00a0Engl J Med. 2023;389(14):1298\u2013309.","journal-title":"N Engl J Med"},{"issue":"3","key":"2358_CR84","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.jad.2008.10.011","volume":"115","author":"V Henkel","year":"2009","unstructured":"Henkel\u00a0V, Seem\u00fcller\u00a0F, Obermeier\u00a0M, Adli\u00a0M, Bauer\u00a0M, Mundt\u00a0C, et\u00a0al. Does early improvement triggered by antidepressants predict response\/remission? Analysis of data from a\u00a0naturalistic study on a\u00a0large sample of inpatients with major depression. J\u00a0Affect Disord. 2009;115(3):439\u201349.","journal-title":"J Affect Disord"},{"issue":"3","key":"2358_CR85","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1037\/pha0000627","volume":"31","author":"EM Peters","year":"2023","unstructured":"Peters\u00a0EM, Halpape\u00a0K, Cheveldae\u00a0I, Wanson\u00a0A. Intranasal racemic ketamine for patients hospitalized with treatment-resistant depression: A\u00a0retrospective analysis. Exp Clin Psychopharmacol. 2023;31(3):593\u20138.","journal-title":"Exp Clin Psychopharmacol"},{"key":"2358_CR86","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.jad.2023.04.141","volume":"335","author":"TM Hietamies","year":"2023","unstructured":"Hietamies\u00a0TM, McInnes\u00a0LA, Klise\u00a0AJ, Worley\u00a0MJ, Qian\u00a0JJ, Williams\u00a0LM, et\u00a0al. The effects of ketamine on symptoms of depression and anxiety in real-world care settings: A\u00a0retrospective controlled analysis. J\u00a0Affect Disord. 2023;335:484\u201392.","journal-title":"J Affect Disord"},{"key":"2358_CR87","doi-asserted-by":"crossref","unstructured":"Buchmayer F, Kasper S. Overcoming the myths of esketamine administration: different and not difficult. Front Psychiatry. 2023;14.","DOI":"10.3389\/fpsyt.2023.1279657"},{"key":"2358_CR88","doi-asserted-by":"crossref","unstructured":"McGrath T, Baskerville R, Rogero M, Castell L. Emerging Evidence for the Widespread Role of Glutamatergic Dysfunction in Neuropsychiatric Diseases. Nutrients. 2022;14(5).","DOI":"10.3390\/nu14050917"},{"key":"2358_CR89","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1146\/annurev-med-053013-062946","volume":"66","author":"CG Abdallah","year":"2015","unstructured":"Abdallah\u00a0CG, Sanacora\u00a0G, Duman\u00a0RS, Krystal\u00a0JH. Ketamine and rapid-acting antidepressants: a\u00a0window into a\u00a0new neurobiology for mood disorder therapeutics. Annu Rev Med. 2015;66:509\u201323.","journal-title":"Annu Rev Med"},{"key":"2358_CR90","doi-asserted-by":"publisher","first-page":"671348","DOI":"10.3389\/fpsyt.2021.671348","volume":"12","author":"R Zheng","year":"2021","unstructured":"Zheng\u00a0R, Zhang\u00a0Y, Yang\u00a0Z, Han\u00a0S, Cheng\u00a0J. Reduced Brain Gray Matter Volume in Patients With First-Episode Major Depressive Disorder: A\u00a0Quantitative Meta-Analysis. Front Psychiatry. 2021;12:671348.","journal-title":"Front Psychiatry"},{"key":"2358_CR91","doi-asserted-by":"publisher","first-page":"110151","DOI":"10.1016\/j.pnpbp.2020.110151","volume":"108","author":"BP Carniel","year":"2021","unstructured":"Carniel\u00a0BP, da Rocha\u00a0NS. Brain-derived neurotrophic factor (BDNF) and inflammatory markers: Perspectives for the management of depression. Prog Neuropsychopharmacol Biol Psychiatry. 2021;108:110151.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"2358_CR92","doi-asserted-by":"publisher","first-page":"109422","DOI":"10.1016\/j.neuropharm.2023.109422","volume":"226","author":"JN Johnston","year":"2023","unstructured":"Johnston\u00a0JN, Kadriu\u00a0B, Allen\u00a0J, Gilbert\u00a0JR, Henter\u00a0ID, Zarate\u00a0CA Jr.. Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment. Neuropharmacology. 2023;226:109422.","journal-title":"Neuropharmacology"},{"key":"2358_CR93","doi-asserted-by":"crossref","unstructured":"Su T, Lu Y, Fu C, Geng Y, Chen Y. GluN2A mediates ketamine-induced rapid antidepressant-like responses. Nat Neurosci. 2023;.","DOI":"10.1038\/s41593-023-01436-y"},{"issue":"3","key":"2358_CR94","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/nm.4050","volume":"22","author":"RS Duman","year":"2016","unstructured":"Duman\u00a0RS, Aghajanian\u00a0GK, Sanacora\u00a0G, Krystal\u00a0JH. Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nat Med. 2016;22(3):238\u201349.","journal-title":"Nat Med"},{"issue":"1","key":"2358_CR95","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41398-021-01318-6","volume":"11","author":"A H\u00f6flich","year":"2021","unstructured":"H\u00f6flich\u00a0A, Kraus\u00a0C, Pfeiffer\u00a0RM, Seiger\u00a0R, Rujescu\u00a0D, Zarate\u00a0CA Jr., et\u00a0al. Translating the immediate effects of S\u2011Ketamine using hippocampal subfield analysis in healthy subjects-results of a\u00a0randomized controlled trial. Transl Psychiatry. 2021;11(1):200.","journal-title":"Transl Psychiatry"},{"issue":"1","key":"2358_CR96","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/s41398-019-0624-1","volume":"9","author":"C Yang","year":"2019","unstructured":"Yang\u00a0C, Yang\u00a0J, Luo\u00a0A, Hashimoto\u00a0K. Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites. Transl Psychiatry. 2019;9(1):280.","journal-title":"Transl Psychiatry"},{"key":"2358_CR97","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.pnpbp.2016.05.007","volume":"71","author":"KG du Jardin","year":"2016","unstructured":"du Jardin\u00a0KG, Muller\u00a0HK, Elfving\u00a0B, Dale\u00a0E, Wegener\u00a0G, Sanchez\u00a0C. Potential involvement of serotonergic signaling in ketamine\u2019s antidepressant actions: A\u00a0critical review. Prog Neuropsychopharmacol Biol Psychiatry. 2016;71:27\u201338.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"2","key":"2358_CR98","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1093\/ijnp\/pyx085","volume":"21","author":"M Spies","year":"2018","unstructured":"Spies\u00a0M, James\u00a0GM, Berroteran-Infante\u00a0N, Ibeschitz\u00a0H, Kranz\u00a0GS, Unterholzner\u00a0J, et\u00a0al. Assessment of Ketamine Binding of the Serotonin Transporter in Humans with Positron Emission Tomography. Int J Neuropsychopharmacol. 2018;21(2):145\u201353.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"10","key":"2358_CR99","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1093\/ijnp\/pyz041","volume":"22","author":"Y Ago","year":"2019","unstructured":"Ago\u00a0Y, Tanabe\u00a0W, Higuchi\u00a0M, Tsukada\u00a0S, Tanaka\u00a0T, Yamaguchi\u00a0T, et\u00a0al. (R)-Ketamine Induces a\u00a0Greater Increase in Prefrontal 5\u2011HT Release Than (S)-Ketamine and Ketamine Metabolites via an AMPA Receptor-Independent Mechanism. Int J Neuropsychopharmacol. 2019;22(10):665\u201374.","journal-title":"Int J Neuropsychopharmacol"},{"key":"2358_CR100","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.nicl.2018.09.001","volume":"20","author":"T Liebe","year":"2018","unstructured":"Liebe\u00a0T, Li\u00a0M, Colic\u00a0L, Munk\u00a0MHJ, Sweeney-Reed\u00a0CM, Woelfer\u00a0M, et\u00a0al. Ketamine influences the locus coeruleus norepinephrine network, with a\u00a0dependency on norepinephrine transporter genotype\u2014a\u00a0placebo controlled fMRI study. Neuroimage Clin. 2018;20:715\u201323.","journal-title":"Neuroimage Clin"},{"key":"2358_CR101","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1360-0443.2011.03576.x","volume":"107(1","author":"CJ Morgan","year":"2012","unstructured":"Morgan\u00a0CJ, Curran\u00a0HV. Independent Scientific Committee on D. Ketamine use: a\u00a0review. Addiction. 2012;107(1):27\u201338.","journal-title":"Addiction"},{"key":"2358_CR102","doi-asserted-by":"crossref","unstructured":"Peng L, Min S, Wei K, Ziemann-Gimmel P. Different regimens of intravenous sedatives or hypnotics for electroconvulsive therapy (ECT) in adult patients with depression. Cochrane Database Syst Rev. 2014;4.","DOI":"10.1002\/14651858.CD009763.pub2"},{"key":"2358_CR103","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jad.2023.02.085","volume":"330","author":"V Millischer","year":"2023","unstructured":"Millischer\u00a0V, Pramhas\u00a0S, Wiedermann\u00a0I, Eder\u00a0V, Kress\u00a0HG, Michalek-Sauberer\u00a0A, et\u00a0al. Comparison of etomidate and methohexital as anesthetic agents for continuation and maintenance electroconvulsive therapy: A\u00a0retrospective analysis of seizure quality and safety. J\u00a0Affect Disord. 2023;330:33\u20139.","journal-title":"J Affect Disord"},{"key":"2358_CR104","doi-asserted-by":"publisher","first-page":"447","DOI":"10.3109\/15622970902960897","volume":"11(2 Pt 2","author":"D Eser","year":"2010","unstructured":"Eser\u00a0D, Nothdurfter\u00a0C, Sch\u00fcle\u00a0C, Damm\u00a0J, Steng\u00a0Y, M\u00f6ller\u00a0HJ, et\u00a0al. The influence of anaesthetic medication on safety, tolerability and clinical effectiveness of electroconvulsive therapy. World J Biol Psychiatry. 2010;11(2 Pt 2):447\u201356.","journal-title":"World J Biol Psychiatry"},{"key":"2358_CR105","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1097\/YCT.0000000000000632","volume":"36(2","author":"NJ Ainsworth","year":"2020","unstructured":"Ainsworth\u00a0NJ, Sepehry\u00a0AA, Vila-Rodriguez\u00a0F. Effects of Ketamine Anesthesia on Efficacy, Tolerability, Seizure Response, and Neurocognitive Outcomes in Electroconvulsive Therapy: A\u00a0Comprehensive Meta-analysis of Double-Blind Randomized Controlled Trials. J\u00a0Ect. 2020;36(2):94\u2013105.","journal-title":"J Ect"},{"key":"2358_CR106","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1097\/YCT.0b013e318283b7e9","volume":"29(3","author":"K J\u00e4rventausta","year":"2013","unstructured":"J\u00e4rventausta\u00a0K, Chrapek\u00a0W, Kampman\u00a0O, Tuohimaa\u00a0K, Bj\u00f6rkqvist\u00a0M, H\u00e4kkinen\u00a0H, et\u00a0al. Effects of S\u2011ketamine as an anesthetic adjuvant to propofol on treatment response to electroconvulsive therapy in treatment-resistant depression: a\u00a0randomized pilot study. J\u00a0Ect. 2013;29(3:158\u201361.","journal-title":"J Ect"},{"key":"2358_CR107","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jad.2017.11.034","volume":"227","author":"M Zhang","year":"2018","unstructured":"Zhang\u00a0M, Rosenheck\u00a0R, Lin\u00a0X, Li\u00a0Q, Zhou\u00a0Y, Xiao\u00a0Y, et\u00a0al. A\u00a0randomized clinical trial of adjunctive ketamine anesthesia in electro-convulsive therapy for depression. J\u00a0Affect Disord. 2018;227:372\u20138.","journal-title":"J Affect Disord"},{"issue":"4","key":"2358_CR108","doi-asserted-by":"publisher","first-page":"554","DOI":"10.4103\/joacp.JOACP_423_19","volume":"37","author":"NR Gaddam","year":"2021","unstructured":"Gaddam\u00a0NR, Kelkar Sasturkar\u00a0VP, Kulkarni\u00a0SJ, Joshi\u00a0PS, Bhale\u00a0PV. A\u00a0comparative study of propofol, thiopentone sodium, and ketofol as induction agents for electro convulsive therapy. J\u00a0Anaesthesiol Clin Pharmacol. 2021;37(4):554\u201360.","journal-title":"J Anaesthesiol Clin Pharmacol"},{"issue":"4","key":"2358_CR109","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1007\/s00540-012-1378-6","volume":"26","author":"S Yalcin","year":"2012","unstructured":"Yalcin\u00a0S, Aydo\u011fan\u00a0H, Selek\u00a0S, Kucuk\u00a0A, Yuce\u00a0HH, Karababa\u00a0F, Bilgi\u00e7\u00a0T. Ketofol in electroconvulsive therapy anesthesia: two stones for one bird. J\u00a0Anesth. 2012;26(4):562\u20137.","journal-title":"J Anesth"},{"issue":"5","key":"2358_CR110","doi-asserted-by":"publisher","first-page":"373","DOI":"10.4103\/ija.IJA_132_17","volume":"61","author":"PK Kadiyala","year":"2017","unstructured":"Kadiyala\u00a0PK, Kadiyala\u00a0LD. Anaesthesia for electroconvulsive therapy: An overview with an update on its role in potentiating electroconvulsive therapy. Indian J Anaesth. 2017;61(5):373\u201380.","journal-title":"Indian J Anaesth"},{"issue":"2","key":"2358_CR111","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/YCT.0000000000000365","volume":"33","author":"Q Chen","year":"2017","unstructured":"Chen\u00a0Q, Min\u00a0S, Hao\u00a0X, Peng\u00a0L, Meng\u00a0H, Luo\u00a0Q, et\u00a0al. Effect of Low Dose of Ketamine on Learning Memory Function in Patients Undergoing Electroconvulsive Therapy\u2014A Randomized, Double-Blind, Controlled Clinical Study. J\u00a0Ect. 2017;33(2):89\u201395.","journal-title":"J Ect"},{"issue":"1","key":"2358_CR112","doi-asserted-by":"publisher","first-page":"e01775","DOI":"10.1002\/brb3.1775","volume":"11","author":"L Zou","year":"2021","unstructured":"Zou\u00a0L, Min\u00a0S, Chen\u00a0Q, Li\u00a0X, Ren\u00a0L. Subanesthetic dose of ketamine for the antidepressant effects and the associated cognitive impairments of electroconvulsive therapy in elderly patients\u2014A randomized, double-blind, controlled clinical study. Brain Behav. 2021;11(1):e1775.","journal-title":"Brain Behav"},{"issue":"8","key":"2358_CR113","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s00406-011-0205-7","volume":"261","author":"L Kranaster","year":"2011","unstructured":"Kranaster\u00a0L, Kammerer-Ciernioch\u00a0J, Hoyer\u00a0C, Sartorius\u00a0A. Clinically favourable effects of ketamine as an anaesthetic for electroconvulsive therapy: a\u00a0retrospective study. Eur Arch Psychiatry Clin Neurosci. 2011;261(8):575\u201382.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"5","key":"2358_CR114","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/S2215-0366(17)30077-9","volume":"4","author":"IM Anderson","year":"2017","unstructured":"Anderson\u00a0IM, Blamire\u00a0A, Branton\u00a0T, Clark\u00a0R, Downey\u00a0D, Dunn\u00a0G, et\u00a0al. Ketamine augmentation of electroconvulsive therapy to improve neuropsychological and clinical outcomes in depression (Ketamine-ECT): a\u00a0multicentre, double-blind, randomised, parallel-group, superiority trial. Lancet Psychiatry. 2017;4(5):365\u201377.","journal-title":"Lancet Psychiatry"},{"issue":"6","key":"2358_CR115","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1192\/bjp.bp.116.189134","volume":"210","author":"G Fernie","year":"2017","unstructured":"Fernie\u00a0G, Currie\u00a0J, Perrin\u00a0JS, Stewart\u00a0CA, Anderson\u00a0V, Bennett\u00a0DM, et\u00a0al. Ketamine as the anaesthetic for electroconvulsive therapy: The KANECT randomised controlled trial. Br J Psychiatry. 2017;210(6):422\u20138.","journal-title":"Br J Psychiatry"},{"issue":"6","key":"2358_CR116","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1192\/bjp.bp.116.195826","volume":"210","author":"A McGirr","year":"2017","unstructured":"McGirr\u00a0A, Berlim\u00a0MT, Bond\u00a0DJ, Chan\u00a0PY, Yatham\u00a0LN, Lam\u00a0RW. Adjunctive ketamine in electroconvulsive therapy: Updated systematic review and meta-analysis. Br J Psychiatry. 2017;210(6):403\u20137.","journal-title":"Br J Psychiatry"},{"issue":"5","key":"2358_CR117","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/S2215-0366(17)30099-8","volume":"4","author":"CH Kellner","year":"2017","unstructured":"Kellner\u00a0CH, Iosifescu\u00a0DV. Ketamine and ECT: better alone than together? Lancet Psychiatry. 2017;4(5):348\u20139.","journal-title":"Lancet Psychiatry"},{"issue":"5","key":"2358_CR118","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/ijnp\/pyab088","volume":"25","author":"J Ekstrand","year":"2022","unstructured":"Ekstrand\u00a0J, Fattah\u00a0C, Persson\u00a0M, Cheng\u00a0T, Nordanskog\u00a0P, \u00c5keson\u00a0J, et\u00a0al. Racemic Ketamine as an Alternative to Electroconvulsive Therapy for Unipolar Depression: A\u00a0Randomized, Open-Label, Non-Inferiority Trial (KetECT). Int J Neuropsychopharmacol. 2022;25(5):339\u201349.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"25","key":"2358_CR119","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1056\/NEJMoa2302399","volume":"388","author":"A Anand","year":"2023","unstructured":"Anand\u00a0A, Mathew\u00a0SJ, Sanacora\u00a0G, Murrough\u00a0JW, Goes\u00a0FS, Altinay\u00a0M, et\u00a0al. Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression. N\u00a0Engl J Med. 2023;388(25):2315\u201325.","journal-title":"N Engl J Med"},{"issue":"10","key":"2358_CR120","first-page":"960","volume":"389","author":"LR Silberbauer","year":"2023","unstructured":"Silberbauer\u00a0LR, Kasper\u00a0S, Spies\u00a0M. Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression. N\u00a0Engl J Med. 2023;389(10):960.","journal-title":"N Engl J Med"},{"issue":"10","key":"2358_CR121","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1056\/NEJMc2308757","volume":"389","author":"SA Souza Jr.","year":"2023","unstructured":"Souza\u00a0SA Jr., Josino\u00a0TR, Bisol\u00a0LW. Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression. N\u00a0Engl J Med. 2023;389(10):959\u201360.","journal-title":"N Engl J Med"},{"issue":"10","key":"2358_CR122","first-page":"960","volume":"389","author":"P Movahed","year":"2023","unstructured":"Movahed\u00a0P, Nordenskj\u00f6ld\u00a0A, Kellner\u00a0CH. Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression. N\u00a0Engl J Med. 2023;389(10):960\u20131.","journal-title":"N Engl J Med"},{"issue":"4","key":"2358_CR123","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/acps.13134","volume":"141","author":"CH Kellner","year":"2020","unstructured":"Kellner\u00a0CH, Obbels\u00a0J, Sienaert\u00a0P. When to consider electroconvulsive therapy (ECT). Acta Psychiatr Scand. 2020;141(4):304\u201315.","journal-title":"Acta Psychiatr Scand"},{"issue":"7","key":"2358_CR124","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1056\/NEJMra2034954","volume":"386","author":"RT Espinoza","year":"2022","unstructured":"Espinoza\u00a0RT, Electroconvulsive Therapy\u00a0KCH. N\u00a0Engl J Med. 2022;386(7):667\u201372.","journal-title":"N Engl J Med"},{"key":"2358_CR125","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1001\/jamapsychiatry.2023.0562","volume":"80(6","author":"V Menon","year":"2023","unstructured":"Menon\u00a0V, Varadharajan\u00a0N, Faheem\u00a0A, Andrade\u00a0C. Ketamine vs Electroconvulsive Therapy for Major Depressive Episode: A\u00a0Systematic Review and Meta-analysis. Jama Psychiatry. 2023;80(6):639\u201342.","journal-title":"Jama Psychiatry"},{"key":"2358_CR126","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1001\/jamapsychiatry.2022.3352","volume":"79(12","author":"TG Rhee","year":"2022","unstructured":"Rhee\u00a0TG, Shim\u00a0SR, Forester\u00a0BP, Nierenberg\u00a0AA, McIntyre\u00a0RS, Papakostas\u00a0GI, et\u00a0al. Efficacy and Safety of Ketamine vs Electroconvulsive Therapy Among Patients With Major Depressive Episode: A\u00a0Systematic Review and Meta-analysis. Jama Psychiatry. 2022;79(12):1162\u201372.","journal-title":"Jama Psychiatry"},{"issue":"11","key":"2358_CR127","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/S2215-0366(22)00317-0","volume":"9","author":"SY Smith-Apeldoorn","year":"2022","unstructured":"Smith-Apeldoorn\u00a0SY, Veraart\u00a0JK, Spijker\u00a0J, Kamphuis\u00a0J, Schoevers\u00a0RA. Maintenance ketamine treatment for depression: a\u00a0systematic review of efficacy, safety, and tolerability. Lancet Psychiatry. 2022;9(11):907\u201321.","journal-title":"Lancet Psychiatry"},{"key":"2358_CR128","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/YCT.0b013e3181719b23","volume":"25(1","author":"KG Rasmussen","year":"2009","unstructured":"Rasmussen\u00a0KG. Sham electroconvulsive therapy studies in depressive illness: a\u00a0review of the literature and consideration of the placebo phenomenon in electroconvulsive therapy practice. J\u00a0Ect. 2009;25(1):54\u20139.","journal-title":"J Ect"},{"issue":"4","key":"2358_CR129","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1001\/jamapsychiatry.2017.0080","volume":"74","author":"G Sanacora","year":"2017","unstructured":"Sanacora\u00a0G, Frye\u00a0MA, McDonald\u00a0W, Mathew\u00a0SJ, Turner\u00a0MS, Schatzberg\u00a0AF, et\u00a0al. A\u00a0Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. Jama Psychiatry. 2017;74(4):399\u2013405.","journal-title":"Jama Psychiatry"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-024-02358-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-024-02358-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-024-02358-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T21:57:58Z","timestamp":1742594278000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-024-02358-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,17]]},"references-count":129,"journal-issue":{"issue":"5-6","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["2358"],"URL":"https:\/\/doi.org\/10.1007\/s00508-024-02358-w","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,17]]},"assertion":[{"value":"29 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.\u00a0Kasper declares that in the past 3 years he has served as a\u00a0consultant or on advisory boards for Angelini, Biogen, Boehringer, Esai, Janssen, IQVIA, Mylan, Recordati, Rovi, Sage and Schwabe and he has served on speakers bureaus for Angelini, Aspen Farmaceutica S.A., Biogen, Janssen, Recordati, Schwabe, Servier, Sothema, and Sun Pharma. Without relevance to this work, P.\u00a0Baldinger-Melich has received research grants within the last 3 years from the Austrian Science Fund (FWF), the Brain and Behaviour Research Foundation (NARSAD Young Investigator Grant) and the Medical-Scientific Fund of the Mayor of the Federal Capital Vienna, and a\u00a0travel grant from Janssen. M.\u00a0Spies has received travel grants from AOP Orphan Pharmaceuticals, Janssen and Austroplant and speaker\/workshop honoraria from Janssen, Austroplant and Eli Lilly. She is a\u00a0board member of the Austrian Society of Neuropsychopharmacology and Biological Psychiatry. R.\u00a0Frey has received speaker\u2019s honoraria, consultation fees and travel support from Janssen and he acted as principal investigator (PI) in the ESCAPE-TRD investigation, a\u00a0multicenter study, sponsored by Janssen. In addition, he has been PI for LivaNova, Alkermes and for the Medical-Scientific Fund of the Mayor of the Federal Capital Vienna (academic study). Speaker\u2019s honoraria have been paid by Lundbeck. D.\u00a0Rujescu served as consultant for Janssen, received honoraria from Boehringer Ingelheim, Gerot Lannacher, Janssen and Pharmagenetix, received travel support from Angelini and Janssen, and served on advisory boards of AC Immune, Roche and Rovi. I.\u00a0Bozic declares that she has no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}